Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01385215 · ClinicalTrials.gov registry record · Early Phase 1
Strategies for Enhancing Mucosal Immunity to Influenza Vaccine
A Early Phase 1 study, sponsored by John Sundy.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
NCT01385215: Completed Early Phase 1 study, sponsored by John Sundy.
NCT01385215 is a Early Phase 1 study that has completed, run by John Sundy. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01385215, a Early Phase 1 study, has completed, sponsored by John Sundy.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and effectiveness of the influenza vaccine when administered nasally and intra-muscular (a "shot" of medicine given into a muscle). The investigators will measure the systemic (through out the body) and mucosal immune responses (how your body recognizes and defends itself against bacteria) to nasally administered influenza vaccine, and determine if nasal immunization results in immunity (your body's ability to avoid infections) within multiple mucosal compartments (ocular (eye), oral and reproductive), in comparison with intramuscular administration and placebo (inactive substance given in the same form as the active drug).
Interventions
- DRUG Fluzone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-04 |
| Est. Completion | 2011-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01385215
The ClinicalTrials.gov registry entry for NCT01385215 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is John Sundy, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fluzone is the first listed.
NCT01385215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01385215 about?
NCT01385215 is a clinical study titled "Strategies for Enhancing Mucosal Immunity to Influenza Vaccine". The purpose of this study is to determine the safety and effectiveness of the influenza vaccine when administered nasally and intra-muscular (a "shot" of medicine given into a muscle). The investigators will measure the systemic (through out the body) and mucosal immune responses (how your body reco...
What is the current status of trial NCT01385215?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2011-04. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01385215?
The interventions under investigation include: Fluzone (DRUG).
Who is sponsoring clinical trial NCT01385215?
This trial is sponsored by John Sundy, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.